2026 Q2 - tulosraportti
40 päivää sitten
‧48 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 501 | - | - | ||
| 1 196 | - | - | ||
| 6 971 | - | - | ||
| 1 300 | - | - | ||
| 1 026 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·16 t sittenInteresting article about what is happening in biotech right now: https://www.finansavisen.no/helse/2026/10/04/8385012/gullrush-i-biotek Nykode is, in my opinion, strategically positioned right in the sweet spot. If you, like me, have great faith in the combination of artificial intelligence and biotech, I think Nykode is the most interesting case on the Oslo Stock Exchange. Part of what I find particularly exciting is the data the company has built up over nearly 20 years. This applies not only to the trials that have succeeded. Also data from experiments that did not yield the desired result can be valuable when teaching models what does not work. All historical data has been preserved, and during the Q&A after the Q2 presentation, Agnete Fredriksen was asked whether new data is fed back into NeoSELECT and used to make the model better over time. The answer was yes. It is precisely this that Finansavisen describes as "lab-in-the-loop": the model suggests, the laboratory tests, the results are fed back, and the next round can be better. This does not mean that AI alone makes Nykode a winner. Clinical results are still what counts. But if Nykode manages to combine 20 years of biological data, NeoSELECT, its own laboratory tests and clinical data in an increasingly better learning loop, then in my opinion it could become a significant competitive advantage. This is a part of the Nykode case that I believe the market is currently paying relatively little attention to. The AI models can eventually be accessed by everyone. 20 years of proprietary biological and clinical data cannot simply be downloaded.
·3 päivää sittenIt goes without saying that they bought over 500,000 :)
Don't know if I would say it "goes without saying" to put that much into a pennystock. With that said, it is a better one of its kind.- ·3 päivää sitten · MuokattuExciting change in the top 50 yesterday, BNP Paribas onto the list with over 1.5 mill shares which means they must have bought at least 50,000 yesterday.
- ·3 päivää sittenNote to self: - next time you don't get to join a share issue because you are not a "bellwether", and feel cheated. Furthermore DO NOT load up on more shares 20% below the issue price —> buy a 2 kg cod at the store, hit yourself in the face.
·1.10.Personally I think the case has actually strengthened recently. In hindsight, it was quite smart to do the private placement while the sentiment around the tax case was positive following the secretariat's recommendation. Today, Nykode is far less dependent on getting back the 325 million than the company was before the private placement. For my part, the price drop has simply provided an opportunity to increase the position at a good discount to the placement price. At the same time, there are several things I am following going forward: Nykode will specify its focus within autoimmune diseases in H1 2027, Abili-T has its first interim data expected in 2027, and I still hope we will see a strategic partner around VB10.NEO. I think the tax case could easily take a long time before we get a final clarification, so I view it more as a potential extra upside than as the case itself. Lots of exciting things happening here. At any rate, I am far more concerned with the pipeline than with some ugly red days on low volume.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
40 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·16 t sittenInteresting article about what is happening in biotech right now: https://www.finansavisen.no/helse/2026/10/04/8385012/gullrush-i-biotek Nykode is, in my opinion, strategically positioned right in the sweet spot. If you, like me, have great faith in the combination of artificial intelligence and biotech, I think Nykode is the most interesting case on the Oslo Stock Exchange. Part of what I find particularly exciting is the data the company has built up over nearly 20 years. This applies not only to the trials that have succeeded. Also data from experiments that did not yield the desired result can be valuable when teaching models what does not work. All historical data has been preserved, and during the Q&A after the Q2 presentation, Agnete Fredriksen was asked whether new data is fed back into NeoSELECT and used to make the model better over time. The answer was yes. It is precisely this that Finansavisen describes as "lab-in-the-loop": the model suggests, the laboratory tests, the results are fed back, and the next round can be better. This does not mean that AI alone makes Nykode a winner. Clinical results are still what counts. But if Nykode manages to combine 20 years of biological data, NeoSELECT, its own laboratory tests and clinical data in an increasingly better learning loop, then in my opinion it could become a significant competitive advantage. This is a part of the Nykode case that I believe the market is currently paying relatively little attention to. The AI models can eventually be accessed by everyone. 20 years of proprietary biological and clinical data cannot simply be downloaded.
- ·3 päivää sittenIt goes without saying that they bought over 500,000 :)Don't know if I would say it "goes without saying" to put that much into a pennystock. With that said, it is a better one of its kind.
- ·3 päivää sitten · MuokattuExciting change in the top 50 yesterday, BNP Paribas onto the list with over 1.5 mill shares which means they must have bought at least 50,000 yesterday.
- ·3 päivää sittenNote to self: - next time you don't get to join a share issue because you are not a "bellwether", and feel cheated. Furthermore DO NOT load up on more shares 20% below the issue price —> buy a 2 kg cod at the store, hit yourself in the face.
- ·1.10.Personally I think the case has actually strengthened recently. In hindsight, it was quite smart to do the private placement while the sentiment around the tax case was positive following the secretariat's recommendation. Today, Nykode is far less dependent on getting back the 325 million than the company was before the private placement. For my part, the price drop has simply provided an opportunity to increase the position at a good discount to the placement price. At the same time, there are several things I am following going forward: Nykode will specify its focus within autoimmune diseases in H1 2027, Abili-T has its first interim data expected in 2027, and I still hope we will see a strategic partner around VB10.NEO. I think the tax case could easily take a long time before we get a final clarification, so I view it more as a potential extra upside than as the case itself. Lots of exciting things happening here. At any rate, I am far more concerned with the pipeline than with some ugly red days on low volume.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 501 | - | - | ||
| 1 196 | - | - | ||
| 6 971 | - | - | ||
| 1 300 | - | - | ||
| 1 026 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
40 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·16 t sittenInteresting article about what is happening in biotech right now: https://www.finansavisen.no/helse/2026/10/04/8385012/gullrush-i-biotek Nykode is, in my opinion, strategically positioned right in the sweet spot. If you, like me, have great faith in the combination of artificial intelligence and biotech, I think Nykode is the most interesting case on the Oslo Stock Exchange. Part of what I find particularly exciting is the data the company has built up over nearly 20 years. This applies not only to the trials that have succeeded. Also data from experiments that did not yield the desired result can be valuable when teaching models what does not work. All historical data has been preserved, and during the Q&A after the Q2 presentation, Agnete Fredriksen was asked whether new data is fed back into NeoSELECT and used to make the model better over time. The answer was yes. It is precisely this that Finansavisen describes as "lab-in-the-loop": the model suggests, the laboratory tests, the results are fed back, and the next round can be better. This does not mean that AI alone makes Nykode a winner. Clinical results are still what counts. But if Nykode manages to combine 20 years of biological data, NeoSELECT, its own laboratory tests and clinical data in an increasingly better learning loop, then in my opinion it could become a significant competitive advantage. This is a part of the Nykode case that I believe the market is currently paying relatively little attention to. The AI models can eventually be accessed by everyone. 20 years of proprietary biological and clinical data cannot simply be downloaded.
- ·3 päivää sittenIt goes without saying that they bought over 500,000 :)Don't know if I would say it "goes without saying" to put that much into a pennystock. With that said, it is a better one of its kind.
- ·3 päivää sitten · MuokattuExciting change in the top 50 yesterday, BNP Paribas onto the list with over 1.5 mill shares which means they must have bought at least 50,000 yesterday.
- ·3 päivää sittenNote to self: - next time you don't get to join a share issue because you are not a "bellwether", and feel cheated. Furthermore DO NOT load up on more shares 20% below the issue price —> buy a 2 kg cod at the store, hit yourself in the face.
- ·1.10.Personally I think the case has actually strengthened recently. In hindsight, it was quite smart to do the private placement while the sentiment around the tax case was positive following the secretariat's recommendation. Today, Nykode is far less dependent on getting back the 325 million than the company was before the private placement. For my part, the price drop has simply provided an opportunity to increase the position at a good discount to the placement price. At the same time, there are several things I am following going forward: Nykode will specify its focus within autoimmune diseases in H1 2027, Abili-T has its first interim data expected in 2027, and I still hope we will see a strategic partner around VB10.NEO. I think the tax case could easily take a long time before we get a final clarification, so I view it more as a potential extra upside than as the case itself. Lots of exciting things happening here. At any rate, I am far more concerned with the pipeline than with some ugly red days on low volume.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 501 | - | - | ||
| 1 196 | - | - | ||
| 6 971 | - | - | ||
| 1 300 | - | - | ||
| 1 026 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt